Online inquiry

IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11526MR)

This product GTTS-WQ11526MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FGFR3 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000142.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2261
UniProt ID P22607
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11526MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14458MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ9420MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IPH-2201
GTTS-WQ1072MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-838
GTTS-WQ4329MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIVV009
GTTS-WQ9643MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ1027MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-399
GTTS-WQ2893MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ7956MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GX-17
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW